A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2017
At a glance
- Drugs Bavituximab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2013 Final results were presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Peregrine Pharmaceuticals media release.
- 20 May 2013 Final results will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Peregrine media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History